Richard G. Vincent - 24 Mar 2022 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role
Chief Financial Officer
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
24 Mar 2022
Net transactions value
+$7,210
Form type
4
Filing time
28 Mar 2022, 16:00:38 UTC
Previous filing
31 Jan 2022
Next filing
01 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Purchase $4.35 +3 +0% $1.45 83,165 24 Mar 2022 Direct
transaction ONCT Common Stock Purchase $516 +356 +0.43% $1.45 83,521 25 Mar 2022 Direct
transaction ONCT Common Stock Purchase $7.4 +5 +0.01% $1.48 83,526 25 Mar 2022 Direct
transaction ONCT Common Stock Purchase $3,182 +2,136 +2.6% $1.49 85,662 25 Mar 2022 Direct
transaction ONCT Common Stock Purchase $3,500 +2,500 +2.9% $1.40 88,162 28 Mar 2022 Direct
holding ONCT Common Stock 4,526 24 Mar 2022 By Family Trust
holding ONCT Common Stock 1,834 24 Mar 2022 By Child
* An asterisk sign (*) next to the price indicates that the price is likely invalid.